GLP-1 Medications: Lose Weight, Protect Your Muscle, Build a Stronger Future
Semaglutide, tirzepatide, and liraglutide can change metabolic health. How you eat, move, and maintain strength helps shape what comes next.
Created by Christopher Caffrey, ACNP, PMHNP, Functional Medicine-trained
October 1st, 2026
Key Takeaways:
Imagine losing 40 pounds. Your clothes fit differently, your blood sugar improves, and getting around feels easier. Those are meaningful wins.
Now imagine the scale keeps dropping, but so does your strength. You are eating very little, skipping meals because you are not hungry, and feeling too depleted to exercise. The weight loss looks successful on paper. Your body may be telling a more complicated story.
GLP-1 medications have changed what is possible in obesity treatment. They can help people make progress after years of frustration. But appetite suppression creates a responsibility: when you eat less, the food you do eat matters more.
The goal is better metabolic health with enough strength to keep living well. That means paying attention to nutrition, muscle, movement, and the years ahead.
First, which medications are we talking about?
Three widely used medications in this conversation are semaglutide, tirzepatide, and liraglutide. Semaglutide and liraglutide activate receptors for GLP-1, a hormone involved in appetite and blood-sugar regulation. Tirzepatide activates both GLP-1 and GIP receptors, making it a dual-action medication.[1–3]
These medicines can reduce hunger, increase fullness, slow stomach emptying, and support insulin release when glucose is elevated. Some people describe having less “food noise”: fewer persistent thoughts about eating.
Medication | Familiar brands* | Common injection schedule | Average weight loss in landmark obesity trials |
Semaglutide | Wegovy; Ozempic | Weekly | About 15% at 68 weeks with semaglutide 2.4 mg |
Tirzepatide | Zepbound; Mounjaro | Weekly | About 15–21% at 72 weeks, depending on dose |
Liraglutide | Saxenda; Victoza | Daily | About 8% at 56 weeks with liraglutide 3 mg |
Wegovy, Zepbound, and Saxenda are brands indicated for weight management; Ozempic, Mounjaro, and Victoza are diabetes brands. Formulations and indications differ, and semaglutide also has oral options. The figures above describe specific injection trials, not every available dose or formulation.[1–6]
These are averages from separate studies, all incorporating lifestyle support. They are not guarantees or a direct comparison. Your medical history, response, tolerability, and access help determine the appropriate choice.
The benefits go beyond a smaller waistline
Reducing excess body fat can improve metabolic health, and these medications can help with glucose control. For someone living with obesity, meaningful weight reduction can also make movement more manageable.[1–6]
Some benefits are established for specific medicines and populations. In SELECT, semaglutide reduced major cardiovascular events by 20% relative to placebo in adults with established cardiovascular disease and overweight or obesity, without diabetes. Events occurred in 6.5% versus 8.0% of participants; this does not mean everyone taking semaglutide receives the same protection.[7]
Zepbound is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity.[2] Research has documented improvements in some inflammatory markers, but that does not make these medications universal treatments for inflammation or every associated illness.[7]
Using medication for obesity is legitimate medical care. The important question is whether treatment improves the person's overall health and ability to function.
Side effects deserve a plan
Nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reflux are common concerns, particularly around dose increases. They can interfere with eating and hydration.[1–3]
Smaller meals, slower eating, and avoiding large, greasy meals may help. Persistent symptoms deserve a conversation with your prescriber; advancing the dose while you cannot eat adequately is a reason to reassess. Adjustments should follow the prescribed treatment plan.
Less common but important risks include gallbladder problems, pancreatitis, serious allergic reactions, and dehydration-related kidney injury. Low blood sugar is more concerning when treatment is combined with insulin or certain diabetes medications. Severe gastroparesis requires particular caution. These medicines carry thyroid-tumor warnings based on animal findings and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2; the human relevance of those animal findings remains uncertain.[1–3]
Severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, or signs of a serious allergic reaction need prompt medical assessment. Weight-loss treatment is inappropriate during pregnancy. Discuss pregnancy plans, eye disease, other medicines, and upcoming anesthesia with your clinician. Tirzepatide can reduce oral hormonal contraceptive effectiveness; its label recommends a non-oral method or added barrier protection for four weeks after starting and after each dose increase.[1,2]
What the scale cannot tell you
When weight falls, some lean tissue often falls with it. This happens with many forms of weight loss, including diet-induced loss; it is not unique to GLP-1 treatment.
In a SURMOUNT-1 body-composition substudy, approximately 75% of the weight lost with tirzepatide was fat and 25% was lean mass. The proportions were similar in the placebo group, although tirzepatide produced greater total loss.[8] A smaller, exploratory STEP 1 analysis also found reductions in both fat and lean mass with semaglutide, with fat declining more.[9]
Lean mass is not identical to skeletal muscle. It includes water and other nonfat tissues. A scan showing lower lean mass does not, by itself, prove muscle disease or declining function.
Still, strength deserves attention. Sarcopenia involves impaired muscle strength and reduced muscle quantity or quality; it is associated with falls, disability, and loss of independence.[10] Someone can have obesity and inadequate muscle reserve at the same time. Older adults, people who are inactive, and those already struggling with weakness warrant particular attention.
Ask more than “How much did I lose?” Ask: “Can I climb stairs more easily? Carry groceries? Get up from a chair? Maintain my training?”
Track what your body can do alongside what it weighs.
Protein matters. So does eating enough.
A quieter appetite can make it easy to drift into coffee for breakfast, a few bites at lunch, and a small dinner. That may produce weight loss while leaving important nutritional needs unmet.
During active weight reduction, protein targets around 1.2–1.6 grams per kilogram per day are often proposed. The appropriate target, and whether to use current, goal, or adjusted weight, should be individualized. Kidney disease and other medical conditions can change the recommendation.[11]
Include a protein source at each meal: eggs, Greek yogurt, fish, poultry, tofu, beans, or lentils. An illustrative starting point is roughly 25–35 grams per meal, adjusted to your total needs. A protein shake can help fill a gap when appetite is low, but should complement a varied diet.[11,16]
Protein is only one piece. Vegetables, fruit, whole grains, legumes, and healthy fats help provide fiber and micronutrients. A Mediterranean-style pattern is one practical option; the best plan also respects your preferences, tolerance, and budget.[16]
Avoid turning medication-assisted weight loss into an unsupervised crash diet. Eating too little can undermine energy and training. Hydration, gradual fiber adjustments, and adequate calcium and vitamin D also deserve attention, with supplements selected for actual needs.[11,16]
Weightlifting belongs in the treatment plan
Protein supplies building materials. Resistance training gives the body a reason to maintain and strengthen muscle.
A 2025 systematic review found that adding resistance exercise to dietary weight loss helped preserve fat-free mass and increased fat loss compared with diet alone. Strength also improved, although evidence certainty varied. These findings support training during weight loss; they do not guarantee zero muscle loss on every medication.[12]
Begin with two strength sessions each week, then progress according to recovery, ability, and goals. U.S. activity guidelines recommend strengthening major muscle groups at least two days weekly, alongside aerobic activity.[14]
You can use weights, machines, bands, or appropriately challenging body-weight exercises. A starting routine might include a squat or chair rise, a row, a wall push-up or press, and a hip-hinge movement. Increase difficulty gradually as technique and strength improve. A trainer or physical therapist can help when pain, balance problems, or unfamiliarity make starting difficult.
Walking remains valuable, but pair it with activities that challenge strength. Work toward about 150 minutes of moderate aerobic activity weekly as tolerated; start smaller if needed.[14]
Exercise may also help protect bone during weight loss. In a liraglutide trial, combining treatment with exercise produced substantial weight loss while preserving lean mass during the treatment phase and avoiding additional hip and spine bone-density loss relative to placebo. This was not proof that exercise prevents fractures with every GLP-1 medication, but it supports a more complete approach.[13]
Could we face a future frailty crisis?
This is a concern worth discussing carefully.
If treatment reaches millions of people while nutrition and strength receive little attention, some may lose useful muscle reserve along with fat. For a person already vulnerable to weakness, that could matter years later, when illness, injury, or aging places greater demands on the body.[8–11]
At a population level, avoidable losses of strength could plausibly contribute to more falls, disability, rehabilitation needs, and dependence on caregivers. That is a potential consequence of inadequate care, not an established national outcome caused by these medications.
Obesity itself carries substantial health risks, and effective treatment can improve health and mobility. Lower lean mass does not automatically mean worse function, especially when someone is carrying much less excess weight. We need long-term studies that measure strength, disability, and fractures, rather than assuming what a body-composition change means.
The sensible response is to build nutrition and strength support into treatment now. We should celebrate better metabolic health while checking that people remain capable, nourished, and active.
How Flexup Wellness Supports the Process
At Flexup Wellness, I approach this as a broader metabolic-health plan. The initial comprehensive consultation creates time to review your history, medications, eating patterns, activity, sleep, stress, and goals, and determine whether medication fits.
Advanced Tracking With the seca TRU Alpha
As part of the Flexup Wellness Partnership, I use the seca TRU Alpha, an advanced body-composition analyzer, for baseline and follow-up assessments. This gives us a more detailed picture of how your body is changing as treatment progresses.
Its analysis provides estimates of skeletal muscle mass in five regions: your right arm, left arm, torso, right leg, and left leg. It also reports total muscle mass, fat mass and body-fat percentage, visceral fat around the abdominal organs, and additional metrics such as body water and phase angle.[17]
Monitoring muscle mass is particularly important during GLP-1 treatment because a lower number on the scale cannot tell us whether you are losing fat, muscle, or a combination of both. Tracking these trends alongside your strength and physical function helps us assess whether progress is consistent with our goal: reducing excess fat while preserving the muscle that supports movement and independence.
For example, if your weight is falling but your muscle estimates and strength are also trending downward, that is a reason to review protein intake, overall nutrition, resistance training, recovery, and medication tolerability. We can adjust the plan rather than simply celebrate another lower weigh-in.
The analyzer uses bioelectrical impedance, so consistent hydration and testing conditions help make repeat assessments more useful. We interpret results alongside your clinical picture and function.
The value is in connecting the measurements to your care. Your follow-up visits give us an opportunity to review body composition, symptoms, intake, strength, and relevant laboratory findings, then make informed adjustments. The aim is to support better metabolic health and protect long-term physical capacity.
Planning also extends to maintenance. In the STEP 1 extension, participants regained roughly two-thirds of their previous weight loss within a year after semaglutide and structured lifestyle support stopped.[15] Healthy habits matter, but they do not guarantee successful medication withdrawal. Some people need ongoing treatment.
Where I Land
GLP-1 medications can be powerful tools. Their value grows when treatment includes adequate nourishment, movement, and attention to function.
The future I want for patients includes better glucose control, less excess fat, and the strength to travel, work, carry groceries, and remain independent.
So when the scale moves, ask what else is changing. Are you eating well? Recovering well? Maintaining strength?
Lose the weight that is harming your health. Protect the capacity that helps you live it.
References
Novo Nordisk. Wegovy prescribing information. Current label accessed October 2026. Official label.
Eli Lilly. Zepbound prescribing information. Current label accessed October 2026. Official label.
Novo Nordisk. Saxenda prescribing information. Current label accessed October 2026. Official label.
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021. doi:10.1056/NEJMoa2032183.
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022. doi:10.1056/NEJMoa2206038.
Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 2015. PubMed.
Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023. doi:10.1056/NEJMoa2307563.
Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16275.
Wilding JPH, et al. Impact of semaglutide on body composition in adults with overweight or obesity: Exploratory analysis of the STEP 1 study. Journal of the Endocrine Society. 2021;5(suppl 1). Conference abstract. Full abstract.
Cruz-Jentoft AJ, et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age and Ageing. 2019. PubMed.
Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from four professional societies. American Journal of Clinical Nutrition. 2025. doi:10.1016/j.ajcnut.2025.04.023.
Binmahfoz A, et al. Effect of resistance exercise on body composition, muscle strength and cardiometabolic health during dietary weight loss in people living with overweight or obesity: A systematic review and meta-analysis. BMJ Open Sport & Exercise Medicine. 2025. doi:10.1136/bmjsem-2024-002363.
Jensen SBK, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: A secondary analysis of a randomized clinical trial. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.16775.
U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans: Key recommendations. Guidance.
Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022. Full study.
Almandoz JP, et al. Nutritional considerations with antiobesity medications. Obesity. 2024. doi:10.1002/oby.24067.
Educational information; medication selection, dosing, nutrition targets, and exercise plans should be individualized.
Comments